Frank L. Jaksch, Jr. Sells 37,161 Shares of ChromaDex Co. (NASDAQ:CDXC) Stock

ChromaDex Co. (NASDAQ:CDXC - Get Free Report) Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares in the company, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ChromaDex Stock Performance

Shares of ChromaDex stock traded down $0.26 during trading hours on Friday, hitting $6.12. The company's stock had a trading volume of 685,166 shares, compared to its average volume of 549,869. The business has a 50 day moving average price of $5.66 and a two-hundred day moving average price of $3.97. ChromaDex Co. has a 12-month low of $1.32 and a 12-month high of $7.97. The company has a market cap of $467.45 million, a PE ratio of 612.61 and a beta of 2.16.

ChromaDex (NASDAQ:CDXC - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The business had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. During the same period last year, the company posted ($0.01) earnings per share. As a group, research analysts anticipate that ChromaDex Co. will post 0.04 earnings per share for the current year.

Institutional Investors Weigh In On ChromaDex

A number of hedge funds and other institutional investors have recently made changes to their positions in CDXC. BSW Wealth Partners purchased a new stake in shares of ChromaDex in the third quarter valued at about $324,000. WINTON GROUP Ltd purchased a new stake in shares of ChromaDex during the second quarter worth approximately $597,000. Marshall Wace LLP acquired a new stake in ChromaDex in the second quarter valued at approximately $56,000. Renaissance Technologies LLC lifted its stake in ChromaDex by 8.4% in the second quarter. Renaissance Technologies LLC now owns 416,100 shares of the company's stock worth $1,136,000 after acquiring an additional 32,400 shares during the last quarter. Finally, Merriman Wealth Management LLC acquired a new position in ChromaDex during the 2nd quarter worth approximately $32,000. Institutional investors and hedge funds own 15.41% of the company's stock.

Wall Street Analyst Weigh In

CDXC has been the subject of a number of recent research reports. Roth Mkm boosted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. StockNews.com raised shares of ChromaDex from a "buy" rating to a "strong-buy" rating in a research note on Monday. Finally, HC Wainwright raised their price objective on ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, November 4th.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.